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Abstract
Background: Several clinical trials and meta-analyses have shown the advantageous effects of statins in populations
with different levels of cardiovascular disease (CVD) risk. Considering the increasing cardiovascular risk among the
Iranian population, the cost-effectiveness of the use of simvastatin 10 mg, as an Over-The-Counter (OTC) drug, for the
primary prevention of myocardial infarction (MI) was evaluated in this modeling study, from the payer's perspective.
The target population is a hypothetical cohort of 45-year CVD healthy men with an average (15 %) 10-year CVD risk.
Methods: A semi-Markov model with a life-long time horizon was developed to evaluate the Cost-Utility-Analysis
(CUA) and Cost-Effectiveness-Analysis (CEA) of the use of OTC simvastatin 10 mg compared to no-drug therapy. Two
measures of benefits were used in the model; Quality-Adjusted-Life-Years (QALYs) for the CUA and Life-Years-Gained
(LYG) for the CEA. To examine the robustness of the results, one-way sensitivity analysis and probabilistic sensitivity
analysis were applied to the model.
Results: For the base-case scenario with a discount rate of 0 % the estimated ICERs were 1113 USD/QALY and 935USD/
LYG per patient (using governmental tariffs).
No threshold has been determined in Iran for the cost-effectiveness of health-related interventions. However, according
to the recommendation of WHO, this intervention can be considered highly cost-effective as its ICER is far less than the
reported GDP per capita for Iran by World bank in 2013 ($4763).
Conclusions: This modeling study showed that the use of an OTC low dose statin (simvastatin 10 mg) for the primary
prevention of myocardial infarction (MI) in 45-year men with a 10-year CVD risk of 15 % could be considered highly
cost-effective in Iran, as it meets the WHO threshold of the annual GDP per capita ($4763).
Keywords: Cost-effectiveness, Cost-utility, myocardial infarction, Markov model, Primary prevention, Simvastatin,
Over-the-counter
Background
Chronic non-communicable diseases (NCDs) are univer-
sally recognized as the major causes of death and disability
[1]. In 2008 around 48 % of NCD-related deaths were re-
ported to be due to cardiovascular diseases (CVDs). It is
predicted that by 2020, CVDs will be responsible for
three-quarters of all deaths in countries with low- and
middle-income [2].
Cardiovascular diseases are the most preventable
causes of death in both developed and developing coun-
tries. The majority of CVD conditions with modifiable
risk factors such as hypertension, dyslipidemia, obesity
and diabetes are preventable or controllable [3]. Several
clinical trials and meta-analyses have shown the advanta-
geous effects of statins for the primary prevention of CVDs
among populations with different levels of CVD risk [4].
Statins are a class of pharmaceuticals used to lower LDL-
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cholesterol levels by inhibiting of the enzyme HMG-COA
reductase [5]. Statins, independent of their lipid-lowering
effect, may also improve endothelial function, inhibit in-
flammatory responses, stabilize atherosclerotic plaques and
show vasculo-protective actions [6]. The indication for the
use of statins also have been suggested for patients with
even low normal LDL cholesterol levels in hopes of favor-
ably altering the incidence of CVDs [7, 8].
To decrease the risk of a first major CVD event in
people who are at moderate risk, the UK medicines
and healthcare products regulatory agency reclassified
simvastatin 10 mg (Zocor Heart-Pro) as an over the
counter(OTC) medicine in 2004. The target popula-
tion includes men aged 55 or more, men aged 45 to
54 years with one or more risk factor, and women aged
55 or more with one or more risk factor [9].
With respect to the increasing prevalence of CVDs
among the Iranian population and its accrued costs, the
cost-effectiveness and cost-utility of the use of 10 mg
simvastatin among 45-year Iranian men with an average
(15 %) 10-year CVD risk from the perspective of payer
were estimated in this study [10].
Methods
The population of this study includes a hypothetical
cohort of CVD-healthy men aged 45 with a 10-year
CVD risk of 15 %.
For chronic disease with recurrent events like as CVD,
particularly when the risk of the disease progression
persists indefinitely, Markov modeling is generally the
preferred choice. Markov models with the transition
probabilities which change with respect to time are named
semi-Markov models [11].
A semi-Markov model was developed to evaluate the
cost-effectiveness and cost-utility of the use of OTC simvas-
tatin10mg (a low dose statin) for the primary prevention of
myocardial infarction (MI) compared to no drug-therapy.
The main measured consequences were LYG for the
CEA and QALY for the CUA.
Life-years-gained is a measure of the benefits from
use of an intervention in terms of increased average life
expectancy or delay of death in the population when
compared with the alternative intervention [12].
Quality-adjusted-life-year is used to illustrate the out-
comes of health care programs through adjusting the life
years gained by an estimate of utility generally measured
using a preference based method [13]. QALYs gained with
treatment therefore incorporate benefits in both quantity
and quality of life.
The choice of cycle length depends upon the interven-
tions of interest as well as the type of disease [14]. For
models with life-long time horizon and relatively rare
events the cycle length can be one year [15]. Majority of
modeling studies on CVD adopted a cycle length of one
year [16]. The current model assumes Markov cycles of
one year and consists of 5 different health states includ-
ing: healthy, non-fatal MI (first year), post-MI, fatal-MI
and death due to any reason other than MI (to prevent
double counting). As in the following years after an
acute (first year) MI, both the treatment costs and the
probability of a recurrent MI are different from the first
year; separated health states for this were considered in
the model (Fig. 1).
In this model, each individual starts as a CVD-healthy
person. A healthy person might develop a non-fatal MI,
die from a fatal MI, or die for any reason other than MI.
Otherwise he would be transferred to the next cycle as a
healthy person. If a patient develops a non-fatal MI, the
patient might experience a new non-fatal MI, die due to a
fatal MI or die for other reasons. If none of these hap-
pened, the patient would be transferred to the next cycle
with a history of MI (post-MI) with the probabilities and
costs related to this health state (which are different from
the first-year MI). Possible transitions from post-MI to
other health states are similar to those of non-fatal MI.
Once patients experience an MI event, they would
receive a POM (Prescription-Only-Medicine) statin (ator-
vastatin 10 mg) in both intervention and no-intervention
groups for life time.
The time horizon of an economic evaluation should be
long enough to be able to capture both the major costs
and the major future outcomes of treatment including
the benefits, potential side effects, morbidity and mortal-
ity. Therefore in many cases a patient’s life time is the
preferred time horizon for the study [14, 17].
Like as many economic evaluation studies on CVD,
this model would be continued until 100 year of age
(when most of the cohort have died) or death [16].
However, due to the nature of Markov models, some
Fig. 1 The Markov model diagram
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proportion of the cohort remain alive, regardless of how
high the applied mortality rates are [18].
For the base-case, a moderate 10-year total CVD risk
of 15 % was taken into account. As the CVD risk rises
with age, an annual increase of 0.03 % in CVD risk was
considered in the model [16]. The proportions of fatal
and non-fatal MI events among total CVD events were
sourced from the Isfahan Cohort Study (ICS) [19]. Dif-
ferent scenarios were evaluated in this modeling study.
For consistency with national studies, a second scenario
was evaluated in which the probabilities of fatal and
non-fatal MI, independent of base-line CVD risk, were
sourced from the ICS population.
As people aged 70 or more could be considered at
high risk of CVD, in a third scenario, a POM statin
(atorvastatin 10 mg) was prescribed from 70 years of age
for the primary prevention, in both intervention and no-
intervention groups [20].
Three different scenarios of discounting were also con-
sidered in this study including: no discounting (0 %), a
discount rate of 3 % for both costs and effects (following
recommendations of the WHO-CHOICE) [21] and a
discount rate of 7.2 % for costs and 3 % for effects,
according to a domestic study [22].
Input parameters, including transition probabilities,
relative risks related to treatment with statins and the
related sources of data are illustrated in Tables 1 and 2.
To calculate QALYs, a utility weights of 0.76 for MI
[16] and 0.88 for post-MI [23] were applied to the
model. To account for diminishing in health with age,
age-related utility weights were also applied to the
model. These utility weights were taken from the Ward
et al. study on statins in 2007 [16].
This study was conducted from the payer's perspective.
Direct costs including drug acquisition costs, laboratory
tests, para-clinical examinations, physician's visits and
hospitalization costs were taken into account. Considering
the selected perspective, indirect costs were not investi-
gated in this study. The costs were expressed in USD, con-
sidering an exchange rate of 26,912 Iranian Rials for each
USD. The applied exchange rate was the monthly average
(from 22.11.2014 to 22.12.2014) reported by the central
bank of Iran [24].
To estimate the unit costs of treatment, we sought
expert clinical advice from the cardiologists of Isfahan
University of Medical Sciences teaching hospitals
(Alzahra hospital and Chamran hospital). The treatment
tariffs were sourced from the last published tariff books
by the Iranian Ministry of Health and Medical Educa-
tion. Also, in different scenarios, two separated series of
tariffs for private and governmental sections were taken
into account [25]. The acquisition cost of each OTC
simvastatin 10 mg tablet (1,100 Rials = 0.041 USD)
sourced from the Food and Drug Organization [26].
For those who received POM statin (atorvastatin 10 mg)
for the primary prevention from 70 years of age, 4 annual
general practitioner visits and two sets of liver function
enzyme tests (SGOTand SGPT) were taken into account.
Table 3 shows the treatment costs used in the model.
We examined the effect of changing several different
parameters in one-way (univariate) sensitivity analyses,
for the base-case scenario. Results from the one-way
sensitivity analyses are presented as Tornado charts.
Also parameter uncertainty was dealt with by probabil-
istic sensitivity analysis for the base-case scenario, using
Monte Carlo simulation with 10,000 iterations for each
evaluation. For each iteration, a value of each input
variable was selected randomly from its distribution
(lognormal distribution for relative risks and costs
and beta distribution for transition probabilities) [27].
The parameters that we varied in the probabilistic
sensitivity analysis (PSA) included relative risks of the
Table 2 The transition probabilities applied in the model
TP/age 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-100 Reference
MI To MI 0.1280 0.1280 0.1152 0.1152 0.1019 0.1019 0.0874 0.0874 0.0711 [16]
MI To FMI 0.0224 0.0348 0.0348 0.0700 0.0700 0.1054 0.1054 0.1270 0.1270 [34–37]
Post-MI To MI 0.0162 0.0162 0.0179 0.0179 0.0185 0.0185 0.0178 0.0178 0.0160 [16]
Post-MI To FMI 0.0052 0.0052 0.0092 0.0092 0.0152 0.0152 0.0235 0.0235 0.0340 [16, 38]
Non MI death 0.0028 0.0043 0.0056 0.0084 0.0131 0.0213 0.0426 0.0705 0.1143 [39, 40]
Healthy To MI (ICS) 0.0031 0.0031 0.0044 0.0044 0.0094 0.0094 0.0061 0.0061 0.0061 [19]
Healthy To FMI (ICS) 0.0015 0.0015 0.0050 0.0050 0.0082 0.0082 0.0080 0.0080 0.0080 [19]
TP = transition probability, MI = non-fatal myocardial infarction in first year, FMI = fatal myocardial infarction, Post-MI = subsequent years of non-fatal myocardial
infarction, ICS = Isfahan Cohort Study
Table 1 Relative risks for the use of statins
The RRa for the use of simvastatin 10 mg
healthy to non-fatal MI 0.752
healthy to fatal MI 0.813
The RRb for the use of atorvastatin 10 mg
healthy to non-fatal MI 0.656
healthy to fatal MI 0.740
aRR = Relative risk, bdata sourced from reference 16
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Table 3 The treatment costs for the first year and following years of MI. The costs in this table were obtained from references 32 &
33
Governmental Private
MI (first year) Post- MI MI (first year) Post-MI


















77.59 2 155.17 - - 230.75 2 461.50 - -
General care units
hospitalization fee (per day)
60.87 2 121.73 - - 180.59 2 361.18 - -
Consultant visit fee 3.72 7 26.01 2 7.43 9.66 7 67.63 2 19.32
General practitioner visit fee 2.97 3 8.92 4 11.89 6.13 3 18.39 4 24.52
-Para-clinical examinations:
Electrocardiogram 3.27 9 29.43 2 6.54 7.43 9 66.88 2 14.86
Echocardiography 35.97 1 35.97 - - 81.75 1 81.75 - -
Exercise tolerance test 18.64 1 18.64 - - 42.36 1 42.36 - -
-Medical laboratory tests:
Lab. patient admission fee 0.45 3 1.34 2 0.89 0.97 3 2.90 2 1.93
Lab. service fee 0.00 3 0.00 2 0.00 0.74 3 2.23 2 1.49
CBC Dif. 0.74 3 2.23 2 1.49 2.01 3 6.02 2 4.01
BUN 0.41 3 1.23 2 0.82 0.89 3 2.68 2 1.78
Cr 0.52 3 1.56 2 1.04 1.08 3 3.23 2 2.16
Na 0.59 3 1.78 2 1.19 1.30 3 3.90 2 2.60
K 0.59 3 1.78 2 1.19 1.30 3 3.90 2 2.60
BS 0.45 3 1.34 2 0.89 0.97 3 2.90 2 1.93
TG 0.71 3 2.12 2 1.41 1.56 3 4.68 2 3.12
Cholesterol 0.52 3 1.56 2 1.04 1.11 3 3.34 2 2.23
PT INR 0.93 1 0.93 - - 1.82 1 1.82
PTT 0.93 1 0.93 - - 1.82 1 1.82 - -
Troponin 2.45 2 4.90 - - 8.62 2 17.24 - -
LDH 1.86 1 1.86 - - 4.35 1 4.35 - -
CPK 2.49 1 2.49 - - 5.39 1 5.39 - -
SGOT 0.63 3 1.90 2 1.26 1.45 3 4.35 2 2.90
SGPT 0.63 3 1.90 2 1.26 1.45 3 4.35 2 2.90
ESR 0.26 1 0.26 - - 0.56 1 0.56 - -
-Pharmaceuticals:
ASA 80 0.01 365 3.66 365 3.66 0.01 365 3.66 365 3.66
Clopidogrel 0.29 365 105.79 - - 0.29 365 105.79 - -
Metoprolol 0.01 365 4.61 365 4.61 0.01 365 4.61 365 4.61
Enoxaparin 3.72 1 3.72 - - 3.72 1 3.72 - -
Atorvastatin10 0.03 365 11.94 365 11.94 0.03 365 11.94 365 11.94
Ranitidine 0.02 30 0.60 - - 0.02 30 0.60 - -
Oxazepam 0.01 4 0.04 - - 0.01 4 0.04 - -
Captopril 0.01 4 0.05 - - 0.01 4 0.05 - -
Streptokinase 9.29 1 9.29 - - 9.29 1 9.29 - -
Drug dispensing fee 0.20 6 1.18 6 1.18 0.59 6 3.57 6 3.57
Total 566.85 59.74 1318.62 112.14
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use of statins for myocardial infarction (±10 %), sec-
ondary MI transition probabilities (±10 %), OTC statin
tablet cost (±25 %), total MI and post-MI treatment
costs (±20 %). Results from the PSA are presented as
scatter plots of incremental cost-effectiveness ratios for
QALY and LYG.
Results
Different scenarios were evaluated in this study includ-
ing the base-case, ICS scenario, in which the primary
transition probabilities were sourced from the ICS study,
and a scenario in which patients in both groups received
a POM statin for the primary prevention from 70 years
of age. Also three different discount rates and two types
of tariffs (governmental and private) were examined for
each scenario. Table 4 shows the obtained results for
these scenarios.
Figures 2, 3, 4 and 5 illustrate the Tornado charts for
the one-way sensitivity analyses. The evaluated data and
the examined range for each of them are shown in the
Table 4 Final results of different scenarios
Cost (USD/Patient) Effect (Per Patient) Incremental results (Per Patient)
Governmental
tariffs



























0 % Base-case 214.70 652.05 445.21 830.02 26.37 26.77 33.82 34.29 1113.40 979.65 935.12 822.79
ICS 261.18 676.05 543.45 896.28 25.84 26.31 33.13 33.69 884.99 752.65 736.79 626.62
POM statin
from 70
463.59 768.23 835.25 1107.22 26.50 26.80 33.98 34.34 1001.43 894.04 863.83 771.19
3 % Base-case 110.71 384.95 231.85 477.97 16.56 16.74 20.71 20.91 1567.74 1407.00 1374.03 1233.16
ICS 128.68 394.62 270.32 504.34 16.37 16.57 20.46 20.70 1309.20 1152.07 1131.89 996.04
POM statin
from 70
204.12 428.42 378.37 581.72 16.60 16.75 20.76 20.93 1526.75 1384.16 1369.28 1241.40
7.2 % for
costs & 3 %
for effects
Base-case 54.91 227.23 116.64 274.35 16.56 16.74 20.71 20.91 985.12 901.62 863.40 790.21
ICS 59.31 229.65 126.25 281.06 16.37 16.57 20.46 20.70 838.56 762.14 724.99 658.92
POM statin
from 70
81.14 239.40 157.83 303.41 16.60 16.75 20.76 20.93 1077.21 990.87 966.11 888.68
Fig. 2 Tornado chart for Incremental cost/QALY per patient (governmental tariffs)
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charts. The Tornado charts show that the incremental-
cost-effectiveness-ratios (ICERs) most affected by the
relative risk of the use of statin and the cost of the OTC
statin tablets.
Figures 6 and 7 for the probabilistic sensitivity analysis
show that the use of OTC simvastatin 10 mg, compared
with no-drug therapy for the primary prevention in 45-
year men with a CVD 10-risk of 15 %, resulted in higher
costs and more LYG and QALYs gained in all of the
simulations. According to the probabilistic sensitivity ana-
lysis, estimated incremental cost per QALY gained and in-
cremental cost per LYG are $1138 (95 % confidence
interval [CI]: $797-$1595) and $960 (95 % confidence
interval [CI]: $663-$1363), respectively. In addition, all the
points comparing OTC simvastatin 10 mg with no-drug
therapy for the primary prevention fell below the recom-
mended threshold of WHO of GDP per capita (the re-
ported GDP per capita by World bank for Iran in 2013
Fig. 3 Tornado chart for Incremental cost/LYG per patient (governmental tariffs)
Fig. 4 Tornado chart for Incremental cost/QALY per patient (private tariffs)
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($4763)) which means the intervention is highly cost-
effective [28].
A cost-effectiveness acceptability curve (CEAC) il-
lustrates the probability that an intervention is more
cost-effective compared with the alternative interven-
tion(s) over a range of ceiling values (λ), representing
the willingness to pay (WTP) for an additional unit of
effectiveness (such as $/QALY) [29, 30].
Figure 8 shows the CEAC for the base-case scenario,
based on the QALY values for OTC statin therapy when
compared to no-drug therapy.
This figure represents the traditional ‘textbook’ case of a
CEAC in which OTC statin therapy is both more costly
and more effective than no-drug therapy. As none of the
pairs represent cost-saving the CEAC cuts the Y-axis at
zero. Also as the whole density involves health gains the
CEAC asymptotes to 1 [31].
A cross-over in acceptability between treatments is
seen at a WTP of $240/QALY. This shows that the
probability of no-drug therapy being more cost-effective
than OTC statin therapy for the primary prevention of
CVD is higher only if the WTP is less than this amount.
Fig. 5 Tornado chart for Incremental cost/LYG per patient (private tariffs)
Fig. 6 PSA Scatter plot of Incremental cost/LYG ratio (governmental tariffs)
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Discussion
There is extensive literature regarding the usefulness of
the use of statins for the primary prevention of CVD.
Considering the increasing risk of MI in the Iranian
population, for the first time, we evaluated the cost-
utility and cost-effectiveness of the use of an OTC low
dose statin (simvastatin 10 mg) for the primary preven-
tion of MI, among middle aged Iranian men with an
average 10-year CVD risk.
We found that for the base-case scenario, simvastatin
10 mg had a cost-utility of $1113 per additional QALY
($979 with private tariffs) and a cost-effectiveness of
$935 per additional LYG ($823 with private tariffs) for
the primary prevention of MI in 45-year-old men with a
15 % 10-year CVD risk.
Although the total cost for health service is higher in
private sector, the difference between intervention and
no-intervention groups in private sector is less than the
same difference in public sector.
The performed scenario analyses produced incremen-
tal costs of no more than $1568 per additional outcome
per patient.
The results of PSA and one-way sensitivity analyses
showed the robustness of our results.
We did not find any other study for the cost-
effectiveness of the use of OTC statins in Iran. The
results of our study is consistent with a previously
published modeling study estimated an incremental
QALYs of 0.06 (with a discount rate of 5 %) for the use
of simvastatin 10 mg for primary prevention in a male
Fig. 7 PSA Scatter plot of Incremental cost/QALY ratio (governmental tariffs)
Fig. 8 CEAC for the base-case scenario (governmental tariffs)
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patient with 15 % 10-year CVD risk. This study differs
from ours in discounting rate, considered health states
and treatment pathways [32].
No threshold has been determined in Iran for the cost-
effectiveness of health-related interventions. However,
considering the 2013 reported GDP per capita for Iran by
World Bank ($4763) [28], the estimated ICERs of this
study show that the evaluated intervention can be consid-
ered highly cost-effective according to WHO recommen-
dations [33].
This analysis has several limitations. We adopted a
payer's perspective and considered only direct medical
costs due to limited data on indirect costs, as well as the
existence of differences among patients in their socio-
economic status and health insurance coverage. We did
not model cardiovascular events other than MI and
patients with cardiovascular risk factors such as hyper-
tension or diabetes. Although we discounted the results
in different scenarios, the effect of inflation was not
taken into account. We also did not have male-specific
data on costs. Due to the limitation of access to imported
branded statins, only domestic generic statin costs were
considered in the model. However, our model's use of
probabilities varying with age, made it more realistic, al-
though much more complex. We also attempted to deal
with uncertainties by performing one-way and probabilis-
tic sensitivity analyses and performing different scenarios.
As a final point, we believe that our modeling study
has important implications for decision-makers in health
practice and policy, particularly in Iran.
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